Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

PEGPH20

Recombinant protein · Acts on hyaluronic acid · developed by Halozyme Therapeutics

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is PEGPH20?

PEGPH20 is a PEGylated recombinant human hyaluronidase that degrades hyaluronic acid in the tumor microenvironment. It is being studied in gastric, gastroesophageal junction, and esophageal adenocarcinomas.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Recombinant protein
Targets
hyaluronic acid
Mechanism
Acts on hyaluronic acid
Pathways
extracellular matrix degradation
Therapy area
Oncology
Developer
Halozyme Therapeutics
In trials of
BLRX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
P01I4980ZS

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03281369 Phase 1/2 Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or… Terminated BLRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.